Highlights;
- President Donald Trump recently commented on cannabis rescheduling, stating, “we’re looking at that” and indicated a determination would be made within the next few weeks.
- The rescheduling process, initiated under President Joe Biden, has been delayed since January due to an interlocutory appeal.
- The Trump administration has several options for moving forward: resuming hearings under a new DEA judge, fast-tracking the proposed rule, starting fresh with a scientific review, or abandoning the reform package.
- U.S. Rep. Greg Steube (R-Fla.) filed the “Marijuana 1-to-3 Act” to reclassify cannabis from Schedule I to Schedule III, criticizing current classifications that equate cannabis with heroin and LSD.
- Other notable cannabis news in August included the Texas Senate passing a hemp THC ban bill, AYR Wellness exiting Massachusetts, and a lawyer revealing he warned New York regulators about buffer zone measurement errors over a year ago.
- These stories were among the top 10 most-read articles in August, as tracked by Cannabis Business Times.
President Donald Trump’s recent remarks on cannabis rescheduling have garnered significant attention, becoming the top story for Cannabis Business Times readers this month. Nearly seven months into his presidency, Trump addressed the topic during an August 11 White House press conference, indicating that the administration is exploring the issue and plans to reach a decision within a few weeks. Notably, he glanced at Attorney General Pam Bondi when discussing the timeline for determining whether to proceed with reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act.
The rescheduling process, initiated under President Joe Biden, was halted by a retired administrative law judge earlier this year and remains pending due to an ongoing interlocutory appeal. The Trump administration now has several options: restarting the hearings with a new DEA judge, fast-tracking the proposed rule, conducting a new scientific review, or abandoning the reform effort altogether.
In related news, U.S. Representative Greg Steube (R-Fla.) introduced the Marijuana 1-to-3 Act Bill, aimed at reclassifying cannabis to Schedule III, just a day after Trump’s comments. Steube criticized the current federal classification of cannabis alongside heroin and LSD, pointing out the inconsistency that cocaine is classified as less restrictive.
Other notable stories this month include Texas passing a hemp THC ban, AYR Wellness exiting Massachusetts, and a lawyer revealing that he had alerted New York regulators about incorrect buffer zone measurements between dispensaries and schools over a year ago.
For more detailed coverage, be sure to explore Cannabis Business Times’ Top 10 stories for August 2025. Additionally, check out their feature on the Best Cannabis Companies to Work For in 2026.
